Mind Cure Health Inc.
CSE: MCUR, FFT: 6MH
Company Overview
- Clinical Research Technology: The company anticipates acquiring diagnostic technologies for use in clinical trials and data collection tools to help clinicians receive patient feedback to improve treatment efficacy.
- Nootropic Formulations: The company is developing nootropic, psychoactive products and substances to promote productivity and enhanced mental health, including products launched under its MoonBeam Mushroom brand.
- Clinical Research: The company intends to evaluate the potential for clinical trials that would benefit mental health and wellness under Health Canada’s industry-leading framework for psychedelic medicines.
- Product Discovery: The company is evaluating the legal and commercial viability of psychedelic compounds such as psilocybin, as well as new and improved psychedelic-inspired candidates, such as non-psychoactive analogs.
- Formulations & Supply: The company is evaluating a path to manufacture, import and supply traditional and novel pharmaceutical agents for North America to satisfy the underserved access to psychoactive compounds APIs for research.
Financial Highlights
$0
Revenue (ttm)
-$45,274
Gross Profit (ttm)
-$0.17
Diluted EPS (ttm)
Management Team
Mr. Philip Tapley
Founder & Chairman
Ms. Kelsey Leigh Ramsden
Pres, CEO & Director
Mr. Michael Andrew Wolfe CA, CPA, M.B.A., MBA
Chief Financial Officer
Mr. Robert C. Hill C.A., CPA, CA, CPA
Independent Director & Corp. Sec.
Mr. Tarik Lebbadi
Chief Operating Officer
Mr. Geoff Belair
Chief Technology Officer
Dr. Joel Raskin
Chief Medical Officer
Mr. Daniel Herrera
VP Of Growth And Strategic Partnerships
Key Highlights
Market Capitalization
$8,110,894
Shares Outstanding
45,220,000
Shares Short (% of Float)
()
Insider Ownership
5%